# Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone

> **NCT06066645** · PHASE3 · RECRUITING · sponsor: **Glaukos Corporation** · enrollment: 230 (estimated)

## Conditions studied

- Glaucoma, Open-Angle

## Interventions

- **DRUG:** Travoprost Intraocular Implant
- **OTHER:** Sham procedure 1
- **DEVICE:** iStent infinite
- **OTHER:** Sham procedure 2

## Key facts

- **NCT ID:** NCT06066645
- **Lead sponsor:** Glaukos Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-09-14
- **Primary completion:** 2027-05
- **Final completion:** 2028-02
- **Target enrollment:** 230 (ESTIMATED)
- **Last updated:** 2026-01-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06066645

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06066645, "Travoprost Intraocular Implant + iStent Infinite vs. iStent Infinite Alone". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06066645. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*